Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
208 hedge funds and large institutions have $3.6B invested in Intra-Cellular Therapies Inc. in 2021 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 57 increasing their positions, 67 reducing their positions, and 21 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
143% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 21
117% more call options, than puts
Call options by funds: $68.2M | Put options by funds: $31.4M
41% more capital invested
Capital invested by funds: $2.56B → $3.6B (+$1.04B)
16% more funds holding
Funds holding: 180 → 208 (+28)
15% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$61.1M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$15.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.3M |
| 4 |
Two Sigma Investments
New York
|
+$11.7M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$9.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$17.9M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$15.7M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$15.5M |
| 4 |
Goldman Sachs
New York
|
-$14.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$11.7M |
ITCI Hedge Fund Activity: Q4 2021 in Review
208 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2021, worth a combined $3.6B — up 41% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ITCI positions and 21 closed out — a net gain of 30 holders — while 57 added to existing stakes and 67 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $61.1M. The largest seller was Citadel Advisors, cutting an estimated $17.9M.
- 208 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2021, up from 180 in Q3 2021.
- Funds reported $3.6B of Intra-Cellular Therapies Inc. stock for Q4 2021, up 41% quarter-over-quarter.
- 51 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2021 and 21 closed out, a net change of +30 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2021 was Pictet Asset Management (Switzerland), an estimated $61.1M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2021 was Citadel Advisors, an estimated $17.9M sold.
Based on aggregated 13F filings for Q4 2021.